Paper Details

  1. Home
  2. Paper Details

Pharmacokinetics and Safety of Long-Acting Release Formulations of Pasireotide (SOM230) in a Male Population Who Are Hyperendemic Hepatitis B/C and Chronic Kidney Disease: An Open-Label, Phase I Study.

Author: HuangChun-Jui, LuChieh-Hua, ShihKuang-Chung

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Pasireotide is a drug used for treating various neuroendocrine tumors. This phase I study investigates the pharmacokinetic profiles and safety of subcutaneous (SC) and long-acting release (LAR) intramuscular injections of pasireotide in Taiwanese volunteers with hyperendemic hepatitis B/C and chronic kidney disease (CKD). The study likely examines drug absorption, elimination, and potential adverse effects in this specific patient population.
Paper Details　
Original Abstract of the Article :
In patients with kidney or hepatic diseases, an increment of circulating pasireotide is also expected. Therefore, this open-label, phase I study aimed to evaluate the pharmacokinetic profiles and safety of subcutaneous (SC) and long-acting release (LAR) intramuscular injections of pasireotide in mal...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s13318-023-00854-4

データ提供：米国国立医学図書館（NLM）

Pasireotide: Exploring a New Oasis in the Desert of Liver and Kidney Disease

I'm Dr. Camel, and I'm always eager to explore new paths in the treatment of liver and kidney diseases. This study examines the pharmacokinetics and safety of pasireotide, a medication used to treat certain hormonal disorders, in patients with hepatitis B/C and chronic kidney disease (CKD). It's like venturing into a desert landscape with unique challenges and seeking to understand how a specific medication might affect the body's delicate balance.

Pasireotide: Navigating a Challenging Terrain

The study investigates the pharmacokinetic profile and safety of long-acting release formulations of pasireotide in a specific population. It's like studying how a caravan might navigate a challenging terrain, taking into account the unique conditions of the environment. The researchers are exploring how the medication is processed and eliminated by the body in patients with liver and kidney diseases. It's like examining the pathways of water flow in a desert, understanding how the body's systems might be impacted by the medication.

A Promising Oasis for Liver and Kidney Disease

This research offers valuable insights into the safety and pharmacokinetics of pasireotide in a specific patient population. It's like discovering a new spring in the desert, providing a potential source of relief and support for those facing liver and kidney disease. The findings could contribute to the development of safer and more effective treatments for these challenging conditions.

Dr.Camel's Conclusion

This open-label, phase I study explores the pharmacokinetics and safety of pasireotide in a population with hepatitis B/C and chronic kidney disease. It's like testing a new route through a desert landscape, seeking to understand its impact on the delicate balance of the body. The study provides valuable data that could inform future research and clinical practice, potentially leading to better treatments for liver and kidney diseases.
Date :
  1. Date Completed 2023-11-06
  2. Date Revised 2023-11-06
Further Info :

Pubmed ID

37751056

DOI: Digital Object Identifier

10.1007/s13318-023-00854-4

Related Literature

Article Analysis
・Effects of pasireotide injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.